|Bid||1.6800 x 0|
|Ask||1.6900 x 0|
|Day's Range||1.6000 - 1.6900|
|52 Week Range||1.4800 - 6.8500|
|Beta (3Y Monthly)||-2.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
VANCOUVER, May 24, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA.V - News) ("Zenabis" or the "Company") is pleased to announce that it has received final approval for the listing of the Company's common shares ("Common Shares") and outstanding listed common share purchase warrants ("Warrants") on the Toronto Stock Exchange (the "TSX"). The Company's Common Shares and Warrants will begin trading on the TSX effective as of market open on May 27, 2019.
VANCOUVER, May 21, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA.V - News) ("Zenabis" or the "Company") today announced the appointment of Natascha Kiernan, an experienced international finance and M&A attorney who has held senior positions at several prominent international law firms, as the newest member of its Board of Directors, effective May 20, 2019. Ms. Kiernan's experience includes working as Counsel in the London office of Skadden, Arps, Slate, Meagher & Flom LLP and she has represented Fortune 500 companies, financial institutions and international governments in complex corporate finance and M&A transactions totalling more than $100 billion in value and spanning six continents. Ms. Kiernan holds a J.D. from Columbia University School of Law and is qualified to practice law in New York and England & Wales.
Construction and licensing continue to progress on track at Zenabis Atholville and Zenabis Langley, with annual design capacity forecast to increase to at least 131,300 kg in the third quarter of 2019. Zenabis has consistently grown more than the previous month's harvest weight from October 2018 to April of 2019.
VANCOUVER, May 13, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA.V - News) ("Zenabis" or the "Company") is pleased to announce the licensing of Phase 2A at its Zenabis Atholville facility (an additional 3,200kg of cannabis cultivation capacity) and disclose the date of its next operational update: May 21, 2019 (for the month of April 2019). This amendment increases licensed operating space from the existing 136,800 square feet at Zenabis Atholville to 174,900 square feet. "Since the creation of Zenabis in January of 2019, we have more than doubled our licensed cultivation capacity from approximately 6,000 kg to 13,400 kg, and we have an additional 9,800 kg of cultivation capacity at Zenabis Atholville submitted and awaiting licensing approval.
Seattle, Washington--(Newsfile Corp. - May 8, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article covering Zenabis Global Inc. (TSXV: ZENA) and its aggressive cannabis production model. With licensed facilities in British Columbia, New Brunswick, and Nova Scotia, near-term and large-scale expansion plans, and supply agreements in place across the country, Zenabis is aiming to take ...
The head of Zenabis Global Inc. (ZENA.V) wants shareholders to know he has skin in the game. He's shunning a salary and bonuses in favour of stock-based compensation.
VANCOUVER, May 2, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA.V - News) ("Zenabis" or the "Company") announces that it has granted an aggregate of 3,755,511 incentive stock options (each, an "Option") to certain independent directors, officers, employees and consultants of the Company in accordance with the Company's stock option plan on its annual grant cycle. The grant date of these options is May 1, 2019. Each Option is exercisable into one common share in the capital of the Company (each, a "Share") at a price of $1.91 per Share, being the closing price of the Shares on the TSX Venture Exchange on April 30, 2019, for a period of three to five years from the date of grant. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
In addition, the Company has filed the financial statements and MD&A for Sun Pharm Investments Ltd. ("Sun Pharm", representing Zenabis' cannabis business prior to the amalgamation with Bevo Agro Inc.) for the year ended December 31, 2018 on SEDAR. Construction is progressing on track at Zenabis Atholville and Zenabis Langley to increase design capacity to at least 131,300 kg by the end of the third quarter of 2019.
VANCOUVER , April 29, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA) (" Zenabis " or the " Company ") is pleased to announce that it has entered into a binding term sheet for a three-year ...
"We are very excited to announce the rollout of our new recreational products as they represent a tangible milestone in our product expansion strategy, which will contribute to overall revenue growth in 2019," stated Andrew Grieve, Chief Executive Officer of Zenabis. The Company's new pre-roll products, initially launched in stores in mid-April, are currently being carried in its key markets of New Brunswick and Nova Scotia.
VANCOUVER, April 22, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA.V - News) ("Zenabis" or the "Company") is pleased to announce that it has received conditional approval to graduate its listing from the TSX Venture Exchange (the "TSXV") to the Toronto Stock Exchange (the "TSX"). "Moving to the main board of one of the largest exchanges in the world is a critical milestone for the Company in terms of demonstrating the strength of our business and expanding our investment appeal to a broader and global audience," stated Andrew Grieve, Chief Executive Officer of Zenabis.
VANCOUVER, April 17, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA.V - News) ("Zenabis" or the "Company") announces today that it has closed its previously announced fully-marketed, "best efforts" offering (the "Offering") of 12,777,777 units of the Company (each, a "Unit"), which includes the exercise of the agents' over-allotment option in full, at a price of $2.25 per Unit, for aggregate gross proceeds to the Company of approximately $28.75 million, before deducting commissions and expenses of the Offering. Each Unit consists of one common share of the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant") to purchase a Common Share at a price of $2.75 for a period of 36 months from today's date. The Warrants have been approved for listing on the TSX Venture Exchange ("TSXV"), under the symbol "ZENA.WT", and trading of the Warrants on the TSXV is expected to commence on April 22, 2019.
VANCOUVER , April 11, 2019 /CNW/ - Trading resumes in: Company: Zenabis Global Inc. TSX-Venture Symbol: ZENA (All Issues) Resumption (ET): 9:30 4/12/2019 IIROC can make a decision to impose a temporary ...
Zenabis Global Inc (ZENA.V) (“Zenabis” or the “Company”) announces that, further to the Company's press release dated April 10, 2019, its fully-marketed, “best efforts” offering (the "Offering") will be of units of the Company (each, a "Unit") at a price of $2.25 per Unit (the "Offering Price"). Each Unit will consist of one common share of the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant") to purchase a Common Share at a price of $2.75 for a period of 36 months following the closing date of the Offering.
VANCOUVER , April 11, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Zenabis Global Inc. TSX-Venture Symbol: ZENA (all issues) Reason: Pending News Halt Time (ET): 10:04:43 AM IIROC ...
Zenabis Global Inc (ZENA.V) (“Zenabis” or the “Company”) announces that it has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated April 9, 2019 (the “Shelf Prospectus”) in connection with a fully-marketed, “best efforts” offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in each of the provinces of Canada, except Québec. The Offering is expected to raise total gross proceeds of approximately $25.0 million before deducting commissions and estimated expenses of the Offering. The Company intends to use the net proceeds of the Offering to fund the cost of conversion of its facilities to cannabis production and for working capital.
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / VANCOUVER , April 10, 2019 /CNW/ - Zenabis Global Inc. (TSXV:ZENA) (" Zenabis " or the " ...